What is the optimal management of cutaneous toxicities caused by EGFRIs?
Epidermal growth factor receptor inhibitors (EGFRIs) are increasingly being used to treat cancer. Toxicities associated with these treatments have the potential to have a significant effect upon an individual’s quality of life, the full impact of which has not been to date fully investigated. These toxicities can lead to a reduction in dose, cessation of anti-cancer treatment and therefore has the potential to influence patient clinical outcomes. This is a pilot study which aims to investigate the extent of this problem both clinically and from the patients’ perspective, develop an assessment tool and evaluate treatments and interventions currently in use. Information from this pilot study will help to identify appropriate intervention(s) which could be tested in a randomised controlled trial (RCT) setting. Furthermore, information from this study has the potential to be utilised in future clinical trials research and practice in assessing and measuring cutaneous toxicities and their impact.
Professor Kate White, Professor Michael Boyer (Sydney Cancer Centre), Keith Cox (Sydney Cancer Centre), Dr Kathleen Scott, Moira Stephens, Dr Heather McKenzie
Professor Kate White
+61 2 9351 9575
Dr Kathleen Scott
+61 2 9351 0582